AbstractBySubCategory

Colorectal Cancer

Gastrointestinal (Colorectal) Cancer

2013 ASCO Annual Meeting

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Effect of 3-5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: FACS randomized controlled trial. D. Mant 3500
Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An alliance for clinical trials in oncology study. C. L. Loprinzi 3501
Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). M. Koopman 3502
Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: A randomized phase III noninferiority trial (SAKK 41/06). D. Koeberle 3503
A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study. J. N. Primrose 3504
FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. A. Falcone 3505
Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC). R. B. Corcoran 3507
A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy. C. Eng 3508
Comprehensive pharmacogenetic profiling of advanced colorectal cancer. A. Madi 3509
Validation of DPYD variants DPYD*2A, I560S, and D949V as predictors of 5-fluorouracil (5-FU)-related toxicity in stage III colon cancer (CC) patients from adjuvant trial NCCTG N0147. A. Lee 3510
Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). K. S. Oliner 3511
Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies. M. Morelli 3512
EGFR and KRAS mutations during anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer: Clinically relevant? L. Karayan-Tapon 3513
Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer. H. Lenz 3514
Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: Results of the GERCOR DREAM phase III trial. C. Tournigand 3515
FOLFIRI plus bevacizumab (bev) as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) who have failed first-line bev plus oxaliplatin-based therapy: The randomized phase III EAGLE study. H. Tamagawa 3516
Effectiveness of bevacizumab added to gold standard chemotherapy in metastatic colorectal cancer (mCRC): Final results from the Itaca randomized clinical trial. A. Passardi 3517
Noninferiority of S-1 to UFT/LV as adjuvant chemotherapy for stage III colon cancer: A randomized phase III trial (ACTS-CC). Y. Nakamoto 3518
A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/l-LV/oxaliplatin (mFOLFOX6) plus bevacizmab in patients with metastatic colorectal cancer: The SOFT study. D. Takahari 3519
Prognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database. D. W. Sommeijer 3520
Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer. M. P. Saunders 3521
BRAF and KRAS mutations as additional risk factors in the context of clinical parameters of patients with colorectal cancer. V. C. Popovici 3522
Prognostic impact of KRAS and BRAFV600E mutations stratified by tumor site in resected stage III colon cancer patients treated with adjuvant mFOLFOX6 with or without cetuximab: NCCTG N0147 (Alliance). F. A. Sinicrope 3523
Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study. J. Flejou 3524
Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab (CTX) in resected stage III colon cancer (CC). J. Taïeb 3525^
Proximal and distal colon tumors as distinct biologic entities with different prognoses. E. Missiaglia 3526
Gene expression profiles and tumor locations in colorectal cancer (left vs. right vs. rectum). M. K. Maus 3527
Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17. S. Y. Brule 3528
MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer. K. P. Raghav 3529
Association of colorectal cancer intrinsic subtypes with prognosis, chemotherapy response, deficient mismatch repair, and epithelial to mesenchymal transition (EMT). R. Salazar 3530
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial. H. Schmoll 3531
Tumor-related and treatment-related colostomy-free survival (CFS) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance 5FU/CisP chemotherapy (CT) in squamous cell carcinoma of the anus (SCCA): Results of ACT II. R. Glynne-Jones 3532
Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database. Q. Shi 3533
Randomized controlled trials (RCTs) examining continuous (CS) versus intermittent strategies (IS) of delivering systemic treatment (Tx) for untreated metastatic colorectal cancer (mCRC): A meta-analysis from the Cancer Care Ontario program in evidence-based care. S. R. Berry 3534
Prospective analysis of UGT1A1 genotyping for predicting toxicities in advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens: Interim safety analysis of a Japanese observational study. W. Ichikawa 3535
Prognostic factors of recurrence of colorectal cancers with microsatellite instability after curative resection: An AGEO retrospective multicenter study. D. Tougeron 3536
Treatment outcome according to tumor ERCC1 expression status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. C. Bokemeyer 3537
Cetuximab and chemotherapy in the treatment of patients with initially “nonresectable” colorectal (CRC) liver metastases: Long-term follow-up of the CELIM trial. G. Folprecht 3538
A phase II study of combination epigenetic therapy in metastatic colorectal cancer (mCRC): A phase II consortium (P2C)/Stand Up 2 Cancer (SU2C) study. N. S. Azad 3539
Using quantitative sensory testing as an early predictor of chronic oxaliplatin neuropathy in gastrointestinal cancer patients. S. M. Reddy 3540
Beyond VEGF inhibition: Comparative efficacy analysis of novel VEGF and non-VEGF therapeutic agents in phase I trials for patients with metastatic colorectal cancer (mCRC). S. R. Patel 3541
5FU/LV with or without irinotecan in patients with resected stage II-III rectal cancer: Final analysis of R98 intergroup study. C. Delbaldo 3542
Phase II trial of target-guided personalized chemotherapy in first-line metastatic colorectal. A. Cubillo 3543
Use of RAS pathway activation or KRAS mutation status to predict cetuximab response in CRC patient-derived xenografts. H. Li 3544
ALK and ROS1 gene rearrangements detected in colorectal cancer (CRC) by fluorescence in situ hybridization (FISH). A. J. Weickhardt 3545
Stereotactic body radiotherapy response and local control rates for hepatic oligometastases. B. Goodman 3546
Effect of oxaliplatin-containing neoadjuvant chemotherapy on tumor volume in locally advanced rectal cancer and sensitivity of surviving tumor cells to radiotherapy. K. Flatmark 3547
Cochrane systematic review and meta-analysis of adjuvant chemotherapy for stage II colon cancer. B. M. Meyers 3548
The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer. K. I. Abdul Jalil 3549
Molecular characteristics and prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX. D. Lee 3550
Proof-of-concept study of Sym004, an anti-EGFR monoclonal antibody (mAb) mixture, in patients (pts) with anti-EGFR mab-refractory KRAS wild-type (wt) metastatic colorectal cancer (mCRC). R. Dienstmann 3551
Association of DNA promoter hypermethylation of decoy receptor 1 (DCR1) with poor response to irinotecan in metastatic colorectal cancer. W. Van Criekinge 3552
Genetic variations in miRNA binding site of TPST1 and ZG16B associated with prognosis for patients with colorectal cancer. B. Kang 3553
Regular statin users and colorectal cancer (CRC) prognosis. W. Ma 3554
Colorectal cancer gene expression profiling using nanostring nCounter analysis. K. K. Ciombor 3555
Neoadjuvant chemoradiotherapy (NCRT) using concurrent S-1 and irinotecan in rectal cancer: Impact on long-term clinical outcomes and prognostic factors. A. Tsutsui 3556
Genes involved in EGFR-degradation to predict for efficacy in metastatic colorectal cancer patients treated with cetuximab. S. Stintzing 3557
Survival after resection plus intra-operative radiofrequency ablation (IRFA) to treat colorectal liver metastases (CLM): Results of an international collaborative study. S. Evrard 3558
Association between c-Met expression and tumor recurrence in colorectal cancer patients after liver resection. H. Shoji 3559
Preoperative radiotherapy (preop RT) in rectal cancer: Impact of chemotherapy on the outcome—Long-term results of the randomized 22,921 phase III trial of EORTC. J. Bosset 3560
Efficacy and toxicity of second-line AIO plus irinotecan (IRI) after pretreatment with AIO plus oxaliplatin (L-OHP) in the sequential therapy of metastatic colorectal cancer (CRC). A. Wein 3561
Hsa-miR-31-3p expression in FFPE tumor samples as a predictor of anti-EGFR response in patients with metastatic colorectal cancer. G. Manceau 3562
Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors. S. Pant 3564
EGFL7 polymorphism to predict tumor response in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI and bevacizumab (BV). J. E. Li 3565
Use of genetic variants in pericyte-driven tumor vessel maturation genes to predict treatment efficacy in mCRC patients treated with FOLFIRI/bevacizumab. N. B. Volz 3566
Use of genetic variants in immune response genes to predict clinical outcome in mCRC patients treated with cetuximab-based therapy. A. M. Schultheis 3567
Use of genetic variants in wnt signaling pathway to predict gender and tumor location dependent survival in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI and bevacizumab (BEV). Y. Ning 3568
Adjuvant chemotherapy (AC) outcomes in young (YP) and elderly patients (EP) with high-risk stage II colon cancer (CC). A. Kumar 3569
Adjuvant chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) versus 5-fluorouracil/leucovorin (FL) in patients with locally advanced rectal cancer after preoperative chemoradiotherapy followed by surgery: A randomized phase II study (The ADORE). Y. Hong 3570
Tumor perivascular PDGFBR as an independent prognostic factor in metastatic colorectal cancer. M. B. Lindh 3571
Primary tumor location and expression of mir-664 as a combined biomarker for bevacizumab effectiveness in metastatic colorectal cancer. M. K. Boisen 3572
On-treatment progression-free survival analysis of ziv-aflibercept/FOLFIRI treatment within 28 days of end of treatment in metastatic colorectal cancer: Updated efficacy results from the VELOUR study. D. Ferry 3573
Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and ziv-aflibercept or placebo in mCRC patients who progressed on prior oxaliplatin treatment. P. Ruff 3574
Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC). T. Pinter 3575
Detection of the BRAFV600E protein in human colon carcinomas by a mutation-specific antibody. T. C. Smyrk 3576
Thymidylate synthase (TS) expression as a prognostic molecular marker in stage II/III colon cancer. D. Klingbiel 3577
Risk of second primary cancers after treatment for locoregional rectal cancer. C. S. Nangia 3578
Influence of sex and anthropometric factors on tumor biologic characteristics of colorectal cancer: A cohort study. J. Brandstedt 3579
Survival benefit and complications of primary tumor resection (PTR) in patients with stage IV colorectal cancer (CRC) in the era of modern chemotherapy: A systematic review and meta-analysis. S. Ahmed 3580
Phase II study of dacarbazine for metastatic colorectal cancer: Final results with MGMT analysis. A. Amatu 3581
Impact of nodal metastasis on survival of stage IV colon cancer: Analysis of National Cancer Data Base (NCDB). M. Shaik 3582
Use of tumor size to predict long-term survival in colon cancer patients: Analysis of National Cancer Data Base (NCDB). S. Saha 3583
Primary tumor resection in metastatic colorectal cancer (mCRC): A prospective cohort study. S. Wong 3584
Final results of the AIO 0307 study: A controlled, randomized, double-blind phase II study of FOLFOX6 or FOLFIRI combined with sorafenib (S) versus placebo (P) in second-line metastatic colorectal carcinoma (mCRC) treatment. T. Hoehler 3586
The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC). H. S. Hochster 3587
Peripheral blood monocytes as biomarkers for colorectal cancer. H. Prenen 3588
Correlation of hypertension and proteinuria with outcomes in elderly bevacizumab (BEV)-treated patients with metastatic colorectal cancer (mCRC): Analysis of the BECOX and BECA studies. A. Salud Salvia 3589
Impact of M1a and M1b staging in patients (pts) with metastatic colorectal cancer. H. F. Kennecke 3590
Prognostic stratification of k-RAS wild type colorectal cancer patients receiving irinotecan-cetuximab treatment: Preliminary results of a prospective study. M. Scartozzi 3591
Association of body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) who received targeted therapies (TT). G. S. Patel 3592
Natural history and outcomes of synchronous and metachronous colorectal cancers (CRC): A population-based analysis. J. Chu 3593
Estrogen and colorectal cancer incidence and mortality in the Women's Health Initiative clinical trial. S. M. Lavasani 3594
A phase II trial of salvage treatment with gemcitabine and S-1 combination in heavily pretreated patients with metastatic colorectal cancer. S. Sym 3595
A French multifactorial prospective study of tumor protein and genetic markers in stage I-III colorectal cancer (CRC): Highlight on molecular characteristics related to mismatch repair (MMR) status. G. Milano 3596
Prognostic significance of tumor stromal and epithelial claudin 2 in metastatic colorectal cancer. A. Mezheyeuski 3597
Aspirin use and survival outcomes in patients (pts) with PIK3CA mutant colorectal cancer (CRC). B. Tran 3598
Hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin plus intravenous cetuximab (Cet) (Optiliv) after failure on one versus two or three chemotherapy protocols in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) (European phase II clinical trial NCT00852228). M. Ducreux 3599
A phase II, randomized, double blind comparison of calcium aluminosilicate clay (CASAD) versus placebo (dibasic calcium carbonate) for the prevention of diarrhea in patients (pts) with metastatic colorectal cancer (mCRC) treated with irinotecan (I). B. K. Kee 3600
Prevention of 5-FU-induced health-threatening toxicity by pretherapeutic DPD deficiency screening: Medical and economic assessment of a multiparametric approach. M. Boisdron-Celle 3601
Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). C. Cremolini 3602
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Traslational analyses from the phase III BEBYP trial. C. Antoniotti 3603
Bevacizumab plus chemotherapy continued beyond first disease progression in patients with metastatic colorectal cancer previously treated with bevacizumab-based therapy: Patterns of disease progression and outcomes based on extent of disease in the ML18147 study. R. Greil 3604
Chemotherapy first, followed by chemoradiation (CRT) and then surgery, in the management of locally advanced rectal cancer (LARC). A. Cercek 3605
Chronomodulated hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil (5-FU), and oxaliplatin (l-OHP) plus intravenous (iv) cetuximab (Cet) (Chrono-Optiliv) in patients with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after treatment failure (European Phase II trial NCT 00852228). M. Bouchahda 3606
The distribution of chromosomal and microsatellite instability in colorectal cancers related to inflammatory bowel disease. S. Brackmann 3607
Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC). J. Lee 3608^
Association of KRAS mutation with worse recurrence-free survival and site of metastatic progression after resection of hepatic colorectal metastases. N. E. Kemeny 3609
Impact of early tumor shrinkage on clinical outcome in KRAS wild-type colorectal liver-limited metastases treated with cetuximab plus chemotherapy: Lessons from a randomized controlled trial. L. Ye 3610
Quality of life (QOL) and toxicity among patients in CALGB 80405. M. J. Naughton 3611
Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients. S. Kopetz 3612
Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts). M. Schirripa 3613
Primary prophylactic granulocyte colony-stimulating factor (GCSF) in Gilbert’s disease patients treated with FOLFIRI first line for metastatic colorectal cancer (mCRC): Final results of the FFCD 0604 study. T. Lecomte 3614
Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP” trial by the Gruppo Oncologico Nord Ovest (GONO). G. Masi 3615
SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC). A. L. Cohn 3616
Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408). S. D. Patterson 3617
Accent-based nomograms (NGs) to predict time to recurrence (TTR) and overall survival (OS) in stage III colon cancer (CC). L. A. Renfro 3618
Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA. T. Gruenberger 3619^
Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). J. Douillard 3620
Phase II clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan-relapsed/refractory metastatic colorectal cancer. N. N. Senzer 3621
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors. J. Tabernero 3622
Discovering new targeted therapies for BRAF mutant-like colorectal cancers. F. A. San Lucas 3623
Predicting overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with chemotherapy (CT): The British Columbia Cancer Agency (BCCA) mCRC score. L. Chen 3624
Phase I dose escalation of the oral histone deacetylase inhibitor (HDACi) resminostat in combination with FOLFIRI in colorectal cancer (CRC) patients: The SHORE trial. H. Schulze-Bergkamen 3625
Effect of EGFR inhibition on HER3/PI3K activation by feedback induction of ErbB heterodimers in cetuximab-sensitive colon cancer cells. B. Jacobs 3626
Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase (DPD) deficiency in patients with colorectal cancer. G. Ahmed 3627
TFAP2E methylation status and prognosis of patients with radically resected colorectal cancer. S. Park 3628
Prognostic biomarkers in a series of stage II colon cancer. C. Santos 3629
Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC. U. R. Mansmann 3630
Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). L. S. Schwartzberg 3631
Clinicopathologic features of KRAS-mutated colorectal tumors vary by site of mutation. V. K. Morris 3632
A phase I study of sorafenib with FOLFIRI as first-line therapy for metastatic colorectal cancer (mCRC): Safety and efficacy results. J. A. Maroun 3633
Ultra-deep amplicon sequencing to identify actionable mutations in matched plasma/tumor specimens from 44 patients with colorectal cancer of UICC stage III and IV. P. Pechanska 3634
Minor response rate to predict patient survival. B. Zhao 3635
Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial. E. Van Cutsem 3636
Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. A. Grothey 3637
Randomized phase III clinical study comparing postoperative UFT/LV,UFT+LV/UFT and UFT+LV+PSK/UFT+PSK as adjuvant therapy for curatively resected stage III colorectal cancer HGCSG-CAD study. T. Shichinohe 3638
Guanylyl cyclase C (GCC) expression in lymph nodes (LNs) as a determinant of recurrence in stage II colon cancer (CC) patients (pts). D. J. Sargent 3639
Real-world comparative economics of a 12-gene assay for prognosis in stage II colon cancer. T. Yu 3640
Gain of ALK gene copy number to predict lack of response to anti-EGFR treatment in advanced chemorefractory colorectal cancer (CRC) with KRAS/NRAS/BRAF/PI3KCA wild-type status. F. Pietrantonio 3641
Bevacizumab before cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin: Analysis of early postoperative complication rate and long term follow-up. C. Eveno 3642
Maintenance with the TLR-9 agonist MGN1703 versus placebo in patients with advanced colorectal carcincoma (mCRC): A randomized phase II trial (IMPACT). J. Riera-Knorrenschild 3643
Association of aspirin use with improved 5-year survival in colorectal cancer patients with PIK3CA mutation. N. Kothari 3644
Time-dependent estimates of recurrence and survival in colon cancer: clinical decision support system tool development for adjuvant therapy and oncological outcome assessment. S. Steele e14500
Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC). A. Cheng e14501
Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC): An interim analysis of the CEBIFOX trial. S. Kasper e14502
CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer. M. van Engeland e14503
A phase Ib study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT). A. R. Townsend e14506
Pharmacodynamic effects of regorafenib in metastatic colorectal carcinoma (mCRC). A. L. Wong e14507
Early prediction of therapeutic efficacy of bevacizumab (Bmab) by measuring plasma concentration of βmab-unconjugated free VEGF-α in patients with recurrent or metastatic colorectal cancer (CRC). Y. Cho e14510
Predictive value of VEGF gene polymorphisms in metastatic colorectal cancer patients treated with a bevacizumab-based chemotherapy. P. Ulivi e14512
Surgical resection of liver metastases and survival outcomes in real-life for metastatic colorectal cancer (mCRC) patients treated in front-line with cetuximab (CTX): The EREBUS cohort. D. M. Smith e14514
Uptake of adjuvant chemotherapy (AC) for colon cancer in older and younger patients (pts) in the Irish population. Z. Rehman e14515
Phase I/II trial of intraperitoneal implantation of agarose-agarose macrobeads (MB) containing mouse renal adenocarcinoma cells (RENCA) in patients (pts) with advanced colorectal cancer (CRC). A. J. Ocean e14517
Correlation of bone marrow micrometastases with nodal status in gastrointestinal tumors. S. Nagpal e14518
The utility of PET scanning in colorectal cancer liver metastases being considered for surgery. J. R. Ismail e14519
Comparing KRAS mutation testing by pyrosequencing versus allele specific primary extension methods in colorectal cancer specimens. K. R. Sampat e14522
Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases. J. Xu e14523
Survival benefit associated with the number of chemotherapy/biologic treatment lines in 5,129 elderly metastatic colon cancer patients. N. Hanna e14524
Accuracy of Wif1 methylated gene test and microbial changes identifying colorectal cancer. I. Sobhani e14525
North American (NA) subgroup results from VELOUR: Ziv-aflibercept versus placebo plus FOLFIRI in mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen. E. P. Mitchell e14528
Survival benefits of adjuvant chemotherapy in high-grade stage II and III colon cancer. W. Tsang e14529
Capecitabine but not 5-FU worsened hepatosplenomegaly and liver function when used with oxaliplatin and cetuximab as first-line treatment in K-ras wild-type metastatic colorectal cancer. V. H. Lee e14530
FDG-PET/CT (PET) in the early prediction of benefit from first-line chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer (mCRC). L. Salvatore e14531
Secondary resection in a general mCRC population with cetuximab-based first-line treatment: Interim analysis of the German noninterventional study ERBITAG. U. P. Neumann e14532
Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer. N. Turan e14533
Multimodality treatment combining chemotherapy, liver surgery, peritoneal resection and hyperthermic intraperitoneal chemotherapy (HIPEC) for metastatic colorectal cancer (mCRC) patients with synchronous liver metastases (LM) and peritoneal carcinomatosis (PC): A multicenter study of the French Association of Surgery. R. Lo Dico e14534
Effect of postoperative chemotherapy (CT) on survival in patients (pts) with resected rectal cancer who received neoadjuvant therapy. C. S. Wu e14535
Influence of KRAS mutations on outcome in patients with curatively resected stage III colon cancer treated with adjuvant chemotherapy. P. Saletti e14536
Risk of tumor-related death in stage I-III colon cance based on gender and tumor location. R. D. Ladner e14538
Association of telomere length with clinical outcomes in patients with colorectal carcinoma. M. A. Baig e14540
Genetic variants in EGFR and its ligands to predict response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. A. Sebio e14541
Cetuximab with irinotecan or oxaliplatin for first-line metastatic colorectal cancer: Effectiveness in the EREBUS cohort compared to pivotal trials. A. Fourrier-Réglat e14542
Association of a polymorphism in amphiregulin with worse prognosis in metastatic colorectal cancer patients treated with cetuximab. P. M. Wilson e14543
Connecting gene expression subtypes of colorectal cancer (CRC) with cell lines and drug resistance. E. Budinska e14544
Safety and efficacy of 90y resin microspheres in elderly (≥70 years) compared to younger patients with colorectal liver metastases (mCRC). A. S. Kennedy e14545
Disparities between young and elderly patients in the first course of treatment for stage II and III rectal cancers. Y. Tilahun e14546
Pooled survival analysis of series using the liver-first approach to the management of colorectal cancer with synchronous liver-limited metastases demonstrates wide variation in outcome. S. Jegatheeswaran e14547
Comparison of circulating tumor cells (CTC) and disseminated tumor cells (DTC) in patients with colorectal carcinoma for a predictive marker for tumor recurrence. H. Sakihama e14548
Functional polymorphism in the microRNA-367 binding site as a prognostic factor for colonic cancer. Y. Chae e14549
Severe falls among older adults with resected stage II/III colon cancer receiving chemotherapy. N. K. LoConte e14550
The efficacy and safety of XELOX plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer: Final report of CCOG-0902 study. N. Hayashi e14552
Reasons for delay in time to initiation of adjuvant chemotherapy (AC) for colon cancer (CC). D. W. Wasserman e14553
Are XELOX and FOLFOX equivalent in colorectal cancer? Dose intensity, toxicity, and treatment duration in clinical practice. Y. Gao e14556
Management of skin toxicity and cetuximab-based regimen compliance in first-line chemotherapy of metastatic colorectal cancer (mCRC) patients (pts): Results of observer study. C. Pinto e14557
Safety and efficacy of the addition of simvastatin to panitumumab in KRAS mutant metastatic colorectal cancer patients. H. Guchelaar e14558
Association between angiotensin-converting enzyme I gene I/d polymorphism and bevacizumab activity in advanced colorectal neoplasm. A. E e14559
Microarray gene expression study of the RESPECT trial for the identification of prognostic and predictive markers. M. Delorenzi e14561
Neoadjuvant treatment response as a tumor necrosis grade for patients with rectal cancer. B. Shim e14563
Is adjuvant oxaliplatin (Ox) overutilized in colon cancer (CC): 408 cases from the practices of 102 oncologists. K. Ziel e14564
Optimal treatment strategy in KRAS wild type (wt) metastatic colorectal cancer (mCRC): Cetuximab plus FOLFIRI followed by FOLFOX4 with or without cetuximab-The Capri trial from the Gruppo Oncologico Dell’Italia Meridionale (GOIM). F. Ciardiello e14565
Association of mesenchymal phenotype in circulating tumor cells with poor prognosis in metastatic colorectal cancer. A. Dasari e14567
Nodal status after preoperative chemoradiotherapy (CRT) in locally advanced rectal cancer: Prognostic evaluation of number of resected lymph nodes (LNs), metastatic resected LNs, and LN ratio in the National Cancer Institute of Brazil. F. M. Vieira e14568
Impact of the Recurrence Score (RS) result and mismatch repair status (MMR) on agreement between oncologists (MDs) for stage II colon cancer (CC) recurrence risk (RR) assessment: A novel clinical utility endpoint for prognostic markers. R. K. Kelley e14569
Primary tumor resection to improve survival in patients with metastatic colorectal cancer in the post-2000 era: A California Cancer Registry analysis. A. M. Rodriguez Fahrni e14570
The "real life" impact of adding bevacizumab to first-line treatment of metastatic colorectal cancer: A retrospective large database study. A. Hammerman e14571
A multicenter dose-finding study of irinotecan (CPT-11) based on UGT1A1 polymorphisms for metastatic colorectal cancer. H. Sato e14572
Quality of life in a multicenter phase II trial of metastasectomy for intra- and extra-hepatic metastases from colorectal adenocarcinoma. A. C. Wei e14573
Risk for developing brain metastases from colorectal cancer in long-term survivors with lung metastases and KRAS mutations. F. Zoratto e14574
Retrospective analysis of dose intensity, toxicity, and clinical outcomes in 5-fluorouracil (5FU)-based regimens in adjuvant treatment of colon cancer. J. Loree e14575
Survival outcomes in U.S. patients with metastatic colorectal cancer: A retrospective database analysis. K. B. Knopf e14576
Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial. F. Marmorino e14577
Lung and colon cancer costs among chemotherapy patients after an FDA policy change. K. Stroupe e14578
Dachshund 2 protein, a novel neuroendocrine marker associated with favorable tumor characteristics and clinical outcome in colorectal cancer. S. Wangefjord e14580
Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status? H. Wong e14583
Safety and efficacy of the addition of simvastatin to cetuximab in KRAS mutant metastatic colorectal cancer patients. J. M. Baas e14586
Is there any difference in overall response rate according to kras mutation in advanced colorectal cancer (aCRC)? J. Rivadeneira Cabana e14589
Clinical characteristics at diagnosis of patients who survive more than 5 years after diagnosis of metastatic colorectal cancer (mCRC). M. Cruz Abrahao e14590
TGFBR1 SNP’s are a genetic marker potentially useful for colorectal cancer screening. M. Pauly e14591
Relationship of the emergence of KRAS mutations and resistance to panitumumab in second-line treatment of colorectal cancer (CRC). K. B. Blagoev e14592
Oxaliplatin given by hepatic arterial infusion (HAI) or systemic (SYS) with capecitabine in patients (pts) with unresectable liverlimited metastasis (Ur-LLM) from colorectal cancer (CRC). B. V. Jensen e14593
Effect of increased body mass index on time to tumor progression in metastatic unresectable colorectal cancer patients treated with bevacizumab-based therapy. I. Yildiz e14594
Retrospective analysis of dose intensity, toxicity, and clinical outcomes in 5-fluorouracil based regimens in the treatment of metastatic colorectal cancer. K. E. Mulder e14595
Worse prognosis of KRAS C.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with first-line triplet chemotherapy plus bevacizumab (FIr-B/FOx) and post-progression. G. Bruera e14596
Phase II trial of cetuximab (Cmab) plus irinotecan (CPT-11) for chemorefractory Japanese patients with advanced and/or metastatic colorectal cancer (mCRC), to evaluate the efficacy and safety based on KRAS, BRAF, PIK3CA, NRAS, and AKT1 mutation status (T-CORE0801). H. Shimodaira e14597
Palliative chemotherapy in advanced colorectal cancer patients age 80 or older. P. Lai e14598
Neoadjuvant pelvic perfusion may facilitate resection of pelvic recurrent rectal cancer. H. J. Wanebo e14599
Hsa-mir-31-3p effects on gene expression in colorectal cancer cell lines and patients. R. Thiébaut e14600
Phase II study of first-line combined chemotherapy bevacizumab with modified RPMI regimen for elderly or frail patients with unresectable or metastatic colorectal cancer (OGSG0802) update analysis. T. Satoh e14601
Use of biologics in addition to chemotherapy in the treatment of elderly Medicare patients with stage IV metastatic colon cancer. C. D. Mullins e14602
Causes of urban-rural disparities in adjuvant chemotherapy (AC) for rectal cancer (RC). K. Rasool Javaheri e14603
The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Analysis of two phase II studies. S. Yuki e14604
Panitumumab after progression on cetuximab in patients with KRAS wild-TYPE (WT) metastatic colorectal cancer (MCRC): A single institution experience. A. Marino e14605
Expression of serpin B5 in colorectal cancer: Its relationship with CEA expression. J. Baek e14606
Cardiac outcomes of raltitrexed in the treatment of colorectal cancer patients with 5-fluorouracil (5-FU) cardiotoxicity. A. Firouzbakht e14607
Understanding why some people with stage III colon cancer do not receive adjuvant chemotherapy. V. Heong e14608
hSRBC promoter CpG island hypermethylation as resistant predictive biomarker of oxaliplatin based chemotherapy in metastasic colorectal cancer patients. C. Moutinho e14609
Prognostic value of incidental betablockers use in metastatic colorectal cancer patients receiving first-line treatment. M. Del Prete e14610
Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study. N. Personeni e14611
Multiplatform assessment of anaplastic lymphoma kinase (ALK) gene rearrangement in signet ring cell carcinoma of the gastrointestinal tract. O. B. Alese e14612
Expression and methylation profiles associated with recurrent mutations in stage II colorectal cancer. L. Pare-Brunet e14613
Addition of bevacizumab to compensate for the negative influence of attenuated relative dose intensity of cytotoxic agents on the outcome in patients with metastatic colorectal cancer. G. Nakayama e14614
Metformin and biomarkers relevant to neoplasia in nondiabetic patients. M. N. Pollak e14615
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. F. Sclafani e14616
Biweekly gemcitabine and capecitabine in heavily pretreated patients with metastatic colorectal cancer (mCRC). M. Solis Hernandez e14617
Novel data processing and image co-registration algorithm for region-specific lipid profiling in colorectal cancer tissue using DESI imaging mass spectrometry. R. Mirnezami e14620
Clinical impact of histologic subtypes and somatic mutations in peritoneal carcinomatosis from colorectal cancer. F. Bibeau e14621
Comparison of efficacy and toxicity of bevacizumab in combination with chemotherapy in the first, second, and third or higher line of treatment for metastatic colorectal carcinoma (mCRC): Data from the Czech multi-institutional registry. I. Kiss e14622
Analysis of totally implantable venous access port systems (TIVAPS) related adverse events (AEs) in metastatic colorectal cancer (mCRC) patients treated with and without bevacizumab. T. Tsushima e14623
Global clinical experience with adjuvant oxaliplatin/5-fluorouracil (5-FU)-based chemotherapy for colon cancer: Outcomes of the ACCElox registry. Y. Park e14624
Comorbidity and other predictors of survival in veterans with colorectal cancer (CRC) at different stages. F. Zhong e14625
Pathway redundancy and feedback loop as drivers of nonresponse in colorectal cancer treatments. H. Kim e14626
Differences in colon cancer incidence rates by latitude. B. K. Shah e14627
Preoperative chemoradiotherapy (QT-RT) with capecitabine and oxaliplatin (CAPOX) in patients with locally advanced rectal cancer. A. Sancho e14628
Thrombotic events in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab. H. O. Al-Shamsi e14630
Methylated miR-124, -137, and -34b/c as predictive biomarkers for ulcerative colitis-associated colorectal neoplasia. Y. Toiyama e14631
Effect of diet-induced obesity on the efficacy of colon cancer treatment in mice. M. W. Greene e14632
A central review of resectability of optimally unresectable colorectal liver metastases following neoadjuvant chemotherapy (KSCC0802). M. Takatsuki e14633
Preclinical model for combined effects of metformin and vitamin D3 on colitis-associated colon neoplasia. W. Li e14634
Association of increased levels of stem cell marker ALDH1 with overall survival in metastatic colon cancer. T. L. Fitzgerald e14635
Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing wave technology. K. Perez e14637
Peripheral immunosuppressive cell levels as predictive marker for the clinical outcome in stage IV colorectal carcinoma. A. Koutoulaki e14639
Patterns of care of elderly patients with metastatic colorectal cancer. S. Parakh e14640
Use of surgery and chemoradiation in stage II and III rectal cancer: A retrospective comparison of treatment modalities in major insurance types using the NCDB. M. Warlaumont e14641
Choice of therapy and time to first treatment for patients with colon cancer: A National Cancer Database analysis. D. C. Olson e14642
Evolving disparities in colorectal cancer control in Texas in the first decade of twenty-first century and implications for cancer control. D. Vugrin e14643
Phase II study of weekly scheduled irinotecan and capecitabine treatment in advanced colorectal cancer patients. W. Li e14644
Is oxaliplatin a good partner for EGFR monoclonal antibodies as first-line treatment in KRAS wild-type metastatic colorectal cancer? A meta-analysis. F. Wen e14645
Improving QOL and safety while reducing costs: Evidence-based adjuvant chemotherapy of colorectal cancer (CRC). W. S. Shimp e14646
Chemotherapy-induced diarrhea in older patients with colorectal cancer receiving fluoropyrimidines: A retrospective review. L. H. Iyer e14647
Tolerability of raltitrexed when it is used in monotherapy and in combination with oxaliplatin (TOMOX) as advanced colorectal cancer treatment in normal clinical practice. M. Constenla e14648
Downstaging after preoperative chemoradiation as a prognostic marker for recurrence after curative surgery in locally advanced rectal cancer. J. Lee e14650
Serum iron levels potential biomarker in FOLFOX/FOLFIRI with or without molecularly targeted drug therapy. T. Ochiai e14651
Mortality risk factors and survival of colon cancer patient. R. Shi e14653
Preclinical activity of lenalidomide in metastatic colorectal cancer. V. Leuci e14654
Hypermethylation of the KEAP1 gene in colorectal cancer and association with disease progression. E. Maiello e14655
Benefit-risk evaluation of ziv-aflibercept in combination with irinotecan-fluoropyrimidine-based chemotherapy (FOLFIRI) from the VELOUR trial using multicriteria decision analysis (MCDA). T. Macarulla e14656
Double KRAS and BRAF mutations in colorectal cancer in a single oncologic department series. P. Guglielmini e14657
Treatment patterns and cost for colorectal cancer by line of therapy and metastasis status. B. S. Seal e14658
Prognostic significance of presence of any mucinous component in curatively resected stage II and III colorectal cancer patients who received adjuvant treatments: Data from a single tertiary center. F. Dane e14660
Comparison of survival predictors in colorectal cancer (CRC) patients of different races. N. Patel e14661
Retrospective analysis of 178 patients with stage I rectum cancer. S. Cihan e14662
Outcomes of oxaliplatin-based adjuvant chemotherapy in pathologically lymph node positive (ypN+) rectal cancer. A. Al Zahrani e14664
Visceral fat as a predictive marker of response to bevacizumab-based treatment in metastatic colorectal cancer. Y. Miyamoto e14665
Locally advanced rectal cancer: The value of magnetic resonance imaging as a predictive tool. L. C. Connell e14666
Effect of microRNA-202-3p on cell proliferation and targeting of ADP-ribosylation factor-like 5A in human colorectal carcinoma. Q. WANG e14667
Leucovorin shortage: Impact on leucovorin/levoleucovorin usage and tx choices in colon cancer patients treated in the United States. A. Katler e14668
Expression of transcription factor Scratch2 in colorectal cancer. K. Ivanov e14669
Neoadjuvant chemoradiotherapy (NACRT) in patients with locally advanced rectal cancer (RC): Results of a phase I/II trial in Japan. T. Koyama e14670
Inmunohistochemical expression of thymidilate synthase, ERCC1, pKDR, and LDH5 as predcitive markers of efficacy in patients with advanced colon cancer treated with XELOX or FOLFOX with or without bevacizumab. J. Garde e14671
Predictive significance of VEGF and HIF-1α expression in metastatic colorectal cancer patients receiving chemotherapy combined with bevacizumab. V. Berk e14672
Association between smoking and tumor grade in colorectal cancer: A retrospective analysis from a single institution. R. Elsoueidi e14673
Impact of K-ras status on FOLFOX and XELOX regimens efficacy in metastatic colorectal (mCRC) patients (pts). M. Fedyanin e14674
Intensive CT scan surveillance for patients who have undergone curative intent treatment for colorectal cancer: The Medstar Washington Hospital Center experience. K. Leventakos e14675
Six years of experience in citoreductive surgery and the application of HIPEC-oxaliplatin. S. Nikolic e14676
Evaluation of treatment benefit to an unselected population of patients with metastatic colorectal cancer, referred to oncological treatment. S. E. Nielsen e14677
UGT1A1*28 polymorphism and vomiting in advanced colorectal cancer. A. E. El Bastawisy e14678
Choice of sequential biologic therapies in metastatic colorectal cancer (mCRC): A cost comparison analysis for wild-type KRAS mCRC patient population in Brazil. R. Weschenfelder e14679
Clinical features and outcome of sporadic colorectal carcinoma in young adults: A single center, cross sectional analysis. M. N. Zahir e14680
Comparison of predictors of survival in colon and rectal cancer patients. Y. M. Tang e14681
Immunihistochemical detection of galNAc-T6 to predict survival in patients with colon cancer. L. Ubillos e14682
Capecitabine plus bevacizumab (Cape-Bev) as a maintenance treatment after induction treatment with FOLFIRI plus bevacizumab (FOLFIRI-Bev) in metastatic colorectal cancer (mCRC). A. M. Tatli e14683
CTLs/regulatory T-cells ratio as a prediction marker of chemotherapy in metastatic colorectal cancer. T. Sasatomi e14684
The study on functions and mechanisms of miR-106b in the metastasis of colorectal cancer. S. Ni e14685
The impact of multidisciplinary cancer conferences (MCC) on the treatment of metastatic rectal cancer (MRC) at the Ottawa Hospital Cancer Centre (TOHCC). T. Di Valentin e14686
Chemokine receptor CXCR4: What is its role in gastrointestinal cancer? L. Lombardi e14687
Association of the polymorphisms of the tandem repeat sequence in the thymidylate synthase gene with tumor stage in colon cancer. S. Aguiar e14688
An overview of clinical and economic outcomes of U.S. veteran colorectal cancer patients. O. Baser e14689
Incidence and impact of K-ras mutation in colorectal cancer (CRC) in a minority population. D. Dietz e14690
Role of clinical variables for predicting pathologic response to neoadjuvant chemoradiation in locally advanced rectal cancer. P. M. Taglietti e14691
Prognosis factors and colorectal cancer survival at Oncologos del Occidente from Colombia, South America. J. A. Chacon Cardona e14692
General epidemiologic colorectal cancer profile in Oncologos del Occidente from Colombia, South America. T. Sanchez Villegas e14693
Sporadic rectal cancers in young adults: Experience from a tertiary cancer center in India. M. Malik e14694
Use of VEGF expression to predict for first-line treatment chemotherapy regimen in metastatic colorectal cancer. M. Ozkan e14695
Can PET CT predict response in locally advanced rectal cancer patients treated with induction FOLFOX? S. Gunduz e14696
Ovarian metastases in colorectal carcinoma. I. Yucel e14697
Safety and feasibility of yttrium-90 (Y-90) treatment for primary and metastatic liver tumors at a community hospital. B. K. Martinez e14698
The role of AP-1 in colon cancer stem cells. M. Chatziioannou e14699
Treatment patterns in metastatic colorectal cancer (mCRC) in Slovakia. T. Salek e14700
Results of monoclonal antibodies against EGFR-receptors application in patients with metastatic colorectal cancer (mCRC). L. Y. Vladimirova e14701
On-chip drug testing of an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor by kinase activity profiling. R. Ruijtenbeek e14702
Clinical colorectal cancer (CRC) subsets in advanced disease: Patterns of metastatic spread to predict survival. M. T. Bourlon e14703
Long-course targeted therapy with bevacizumab to predict better survival in patients with advanced colorectal cancer. Y. Deng e14704
The efficacy and safety of first-line and salvage therapies with bevacizumab combination chemotherapy regimens in metastatic colorectal cancer: A retrospective ASMO experience. R. Yildiz e14705
Third line chemotherapy in metastatic colorectal cancer: A single institution experience. W. F. Carbonel Luyo e14706
Restoration of pro-death function of BAX MSI mutation for selective chemotherapy in colorectal cancer cells. H. Zhang e14707
Defective mismatch repair proteins and microsatellite instability in young Mexican patients with colorectal cancer. A. Quintanilla Guzman e14708
Diabetes as a predictor of colon cancer prognosis: A single institution based retrospective data analysis. N. Ammannagari e14709
Plasma TIMP-1 in patients with metastatic colorectal cancer treated with first-line oxaliplatin-based therapy with or without cetuximab: Results from the Nordic VII study. L. S. Tarpgaard e14710
Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouracil, and leucovorin versus oxaliplatin, 5-fluorouracil, and leucovorin versus 5-fluorouracil and leucovorin for patients with stage II or III rectal cancer receiving either preoperative radiation and 5-fluorouracil or postoperative radiation and 5-fluorouracil: ECOG E3201—An updated survival analysis. H. S. Nimeiri e14711
Preoperative chemoradiotherapy (QT-RT) with capecitabine and oxaliplatin (CAPOX) or capecitabine alone (CAP) in patients (PTS) with locally advanced rectal cancer (LARC). I. Marrodan e14712
Incidence and risk of hand foot skin reaction (HFSR) in patients receiving regorafenib for cancer: A meta-analysis. V. Belum e14713
Prediction of tumor recurrence by tumor location in stage II and III colon cancer patients through common germ-line variants of genes involved in wnt signaling pathway. W. Zhang e14714
Efficacy and safety of single agent (SA) or combination (CO) adjuvant chemotherapy (AC) in elderly patients with colon cancer: A Canadian Cancer Institute experience. C. Kim e14715
Pathologic response, KRAS status, and bevacizumab: The Bermuda triangle for outcome prediction after hepatic colorectal cancer metastases (HCRM) resection. G. Fanetti e14716
Clinical impact of first response evaluation (FRE) in metastatic colorectal cancer (mCRC) patients (pts) treated with a cetuximab-based regimen (C-R): Results of a mono-institutional experience. F. L. Rojas Llimpe e14717
Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). V. Heinemann LBA3506
FOCUS4: A prospective molecularly stratified, adaptive multicenter program of randomized controlled trials for patients with colorectal cancer (CRC). K. Shiu TPS3645
MLN0264, an investigational, first-in-class antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC): Phase I, first-in-human study in patients (pts) with advanced gastrointestinal (GI) malignancies expressing GCC. K. Almhanna TPS3646
A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21). C. M. Booth TPS3647
Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification). S. Marsoni TPS3648
ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation. E. Segelov TPS3649